ID   CARM1_MOUSE             Reviewed;         608 AA.
AC   Q9WVG6; Q3TYB9; Q8K1Y5; Q91W24; Q99KX8;
DT   04-JAN-2005, integrated into UniProtKB/Swiss-Prot.
DT   13-SEP-2004, sequence version 2.
DT   07-APR-2021, entry version 169.
DE   RecName: Full=Histone-arginine methyltransferase CARM1;
DE            EC=2.1.1.319 {ECO:0000269|PubMed:11341840, ECO:0000269|PubMed:17882261, ECO:0000269|PubMed:19843527, ECO:0000269|PubMed:19897492, ECO:0000269|PubMed:21138967};
DE   AltName: Full=Coactivator-associated arginine methyltransferase 1;
DE   AltName: Full=Protein arginine N-methyltransferase 4;
GN   Name=Carm1; Synonyms=Prmt4;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), MUTAGENESIS OF 189-VAL--ASP-191,
RP   FUNCTION, TISSUE SPECIFICITY, METHYLATION OF HISTONE H3, AND INTERACTION
RP   WITH NCOA1; NCOA2 AND NCOA3.
RC   TISSUE=Embryo;
RX   PubMed=10381882; DOI=10.1126/science.284.5423.2174;
RA   Chen D., Ma H., Hong H., Koh S.S., Huang S.-M., Schurter B.T., Aswad D.W.,
RA   Stallcup M.R.;
RT   "Regulation of transcription by a protein methyltransferase.";
RL   Science 284:2174-2177(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND NUCLEOTIDE SEQUENCE
RP   [LARGE SCALE MRNA] OF 261-608 (ISOFORM 1).
RC   STRAIN=FVB/N; TISSUE=Mammary gland, and Mammary tumor;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 17-608 (ISOFORM 1).
RC   STRAIN=C57BL/6J; TISSUE=Visual cortex;
RX   PubMed=16141072; DOI=10.1126/science.1112014;
RA   Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N.,
RA   Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K.,
RA   Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M., Davis M.J.,
RA   Wilming L.G., Aidinis V., Allen J.E., Ambesi-Impiombato A., Apweiler R.,
RA   Aturaliya R.N., Bailey T.L., Bansal M., Baxter L., Beisel K.W., Bersano T.,
RA   Bono H., Chalk A.M., Chiu K.P., Choudhary V., Christoffels A.,
RA   Clutterbuck D.R., Crowe M.L., Dalla E., Dalrymple B.P., de Bono B.,
RA   Della Gatta G., di Bernardo D., Down T., Engstrom P., Fagiolini M.,
RA   Faulkner G., Fletcher C.F., Fukushima T., Furuno M., Futaki S.,
RA   Gariboldi M., Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E.,
RA   Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N., Hill D.,
RA   Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T., Jakt M.,
RA   Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H., Kitano H.,
RA   Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K., Kurochkin I.V.,
RA   Lareau L.F., Lazarevic D., Lipovich L., Liu J., Liuni S., McWilliam S.,
RA   Madan Babu M., Madera M., Marchionni L., Matsuda H., Matsuzawa S., Miki H.,
RA   Mignone F., Miyake S., Morris K., Mottagui-Tabar S., Mulder N., Nakano N.,
RA   Nakauchi H., Ng P., Nilsson R., Nishiguchi S., Nishikawa S., Nori F.,
RA   Ohara O., Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G.,
RA   Pesole G., Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z.,
RA   Ringwald M., Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C.,
RA   Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y.,
RA   Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B., Sperling S.,
RA   Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K., Tammoja K.,
RA   Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A., Ueda H.R.,
RA   van Nimwegen E., Verardo R., Wei C.L., Yagi K., Yamanishi H.,
RA   Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C., Grimmond S.M.,
RA   Teasdale R.D., Liu E.T., Brusic V., Quackenbush J., Wahlestedt C.,
RA   Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y., Fukuda S.,
RA   Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T., Iida J., Imamura K.,
RA   Itoh M., Kato T., Kawaji H., Kawagashira N., Kawashima T., Kojima M.,
RA   Kondo S., Konno H., Nakano K., Ninomiya N., Nishio T., Okada M., Plessy C.,
RA   Shibata K., Shiraki T., Suzuki S., Tagami M., Waki K., Watahiki A.,
RA   Okamura-Oho Y., Suzuki H., Kawai J., Hayashizaki Y.;
RT   "The transcriptional landscape of the mammalian genome.";
RL   Science 309:1559-1563(2005).
RN   [4]
RP   FUNCTION IN METHYLATION OF HISTONE H3, AND CATALYTIC ACTIVITY.
RX   PubMed=11341840; DOI=10.1021/bi002631b;
RA   Schurter B.T., Koh S.S., Chen D., Bunick G.J., Harp J.M., Hanson B.L.,
RA   Henschen-Edman A., Mackay D.R., Stallcup M.R., Aswad D.W.;
RT   "Methylation of histone H3 by coactivator-associated arginine
RT   methyltransferase 1.";
RL   Biochemistry 40:5747-5756(2001).
RN   [5]
RP   METHYLATION OF HISTONE H3.
RX   PubMed=11747826; DOI=10.1016/s0960-9822(01)00600-5;
RA   Ma H., Baumann C.T., Li H., Strahl B.D., Rice R., Jelinek M.A., Aswad D.W.,
RA   Allis C.D., Hager G.L., Stallcup M.R.;
RT   "Hormone-dependent, CARM1-directed, arginine-specific methylation of
RT   histone H3 on a steroid-regulated promoter.";
RL   Curr. Biol. 11:1981-1985(2001).
RN   [6]
RP   FUNCTION, METHYLATION OF EP300 AND CREBBP, MUTAGENESIS OF 189-VAL--ASP-191,
RP   AND INTERACTION WITH EP300 AND CREBBP.
RX   PubMed=11701890; DOI=10.1126/science.1065961;
RA   Xu W., Chen H., Du K., Asahara H., Tini M., Emerson B.M., Montminy M.,
RA   Evans R.M.;
RT   "A transcriptional switch mediated by cofactor methylation.";
RL   Science 294:2507-2511(2001).
RN   [7]
RP   METHYLATION OF HISTONE H3.
RX   PubMed=12498683; DOI=10.1016/s0960-9822(02)01387-8;
RA   Daujat S., Bauer U.-M., Shah V., Turner B., Berger S., Kouzarides T.;
RT   "Crosstalk between CARM1 methylation and CBP acetylation on histone H3.";
RL   Curr. Biol. 12:2090-2097(2002).
RN   [8]
RP   METHYLATION OF HISTONE H3.
RX   PubMed=11751582; DOI=10.1093/embo-reports/kvf013;
RA   Bauer U.-M., Daujat S., Nielsen S.J., Nightingale K., Kouzarides T.;
RT   "Methylation at arginine 17 of histone H3 is linked to gene activation.";
RL   EMBO Rep. 3:39-44(2002).
RN   [9]
RP   METHYLATION OF PABPC1.
RX   PubMed=11850402; DOI=10.1093/embo-reports/kvf052;
RA   Lee J., Bedford M.T.;
RT   "PABP1 identified as an arginine methyltransferase substrate using high-
RT   density protein arrays.";
RL   EMBO Rep. 3:268-273(2002).
RN   [10]
RP   FUNCTION, SUBCELLULAR LOCATION, DEVELOPMENTAL STAGE, AND INTERACTION WITH
RP   MEF2C.
RX   PubMed=11713257; DOI=10.1074/jbc.m109835200;
RA   Chen S.L., Loffler K.A., Chen D., Stallcup M.R., Muscat G.E.;
RT   "The coactivator-associated arginine methyltransferase is necessary for
RT   muscle differentiation: CARM1 coactivates myocyte enhancer factor-2.";
RL   J. Biol. Chem. 277:4324-4333(2002).
RN   [11]
RP   FUNCTION, MUTAGENESIS OF GLU-267, AND INTERACTION WITH CTNNB1.
RX   PubMed=11983685; DOI=10.1074/jbc.m110865200;
RA   Koh S.S., Li H., Lee Y.-H., Widelitz R.B., Chuong C.-M., Stallcup M.R.;
RT   "Synergistic coactivator function by coactivator-associated arginine
RT   methyltransferase (CARM) 1 and beta-catenin with two different classes of
RT   DNA-binding transcriptional activators.";
RL   J. Biol. Chem. 277:26031-26035(2002).
RN   [12]
RP   METHYLATION OF ELAVL1.
RX   PubMed=12237300; DOI=10.1074/jbc.m206187200;
RA   Li H., Park S., Kilburn B., Jelinek M.A., Henschen-Edman A., Aswad D.W.,
RA   Stallcup M.R., Laird-Offringa I.A.;
RT   "Lipopolysaccharide-induced methylation of HuR, an mRNA-stabilizing
RT   protein, by CARM1. Coactivator-associated arginine methyltransferase.";
RL   J. Biol. Chem. 277:44623-44630(2002).
RN   [13]
RP   CHARACTERIZATION, AND HOMOOLIGOMERIZATION.
RX   PubMed=12351636; DOI=10.1074/jbc.m207623200;
RA   Teyssier C., Chen D., Stallcup M.R.;
RT   "Requirement for multiple domains of the protein arginine methyltransferase
RT   CARM1 in its transcriptional coactivator function.";
RL   J. Biol. Chem. 277:46066-46072(2002).
RN   [14]
RP   FUNCTION, IDENTIFICATION IN A COMPLEX WITH EP300 AND NCOA2, AND MUTAGENESIS
RP   OF GLU-267.
RX   PubMed=11997499; DOI=10.1128/mcb.22.11.3621-3632.2002;
RA   Lee Y.-H., Koh S.S., Zhang X., Cheng X., Stallcup M.R.;
RT   "Synergy among nuclear receptor coactivators: selective requirement for
RT   protein methyltransferase and acetyltransferase activities.";
RL   Mol. Cell. Biol. 22:3621-3632(2002).
RN   [15]
RP   FUNCTION, DISRUPTION PHENOTYPE, AND METHYLATION OF PABPC1.
RX   PubMed=12756295; DOI=10.1073/pnas.1232272100;
RA   Yadav N., Lee J., Kim J., Shen J., Hu M.C.-T., Aldaz C.M., Bedford M.T.;
RT   "Specific protein methylation defects and gene expression perturbations in
RT   coactivator-associated arginine methyltransferase 1-deficient mice.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:6464-6468(2003).
RN   [16]
RP   FUNCTION, AND INTERACTION WITH TP53.
RX   PubMed=15186775; DOI=10.1016/j.cell.2004.05.009;
RA   An W., Kim J., Roeder R.G.;
RT   "Ordered cooperative functions of PRMT1, p300, and CARM1 in transcriptional
RT   activation by p53.";
RL   Cell 117:735-748(2004).
RN   [17]
RP   METHYLATION OF HISTONE H3.
RX   PubMed=15339660; DOI=10.1016/j.cell.2004.08.020;
RA   Cuthbert G.L., Daujat S., Snowden A.W., Erdjument-Bromage H., Hagiwara T.,
RA   Yamada M., Schneider R., Gregory P.D., Tempst P., Bannister A.J.,
RA   Kouzarides T.;
RT   "Histone deimination antagonizes arginine methylation.";
RL   Cell 118:545-553(2004).
RN   [18]
RP   FUNCTION, AND INTERACTION WITH FLII.
RX   PubMed=14966289; DOI=10.1128/mcb.24.5.2103-2117.2004;
RA   Lee Y.-H., Campbell H.D., Stallcup M.R.;
RT   "Developmentally essential protein flightless I is a nuclear receptor
RT   coactivator with actin binding activity.";
RL   Mol. Cell. Biol. 24:2103-2117(2004).
RN   [19]
RP   METHYLATION OF HISTONE H3, FUNCTION, AND INTERACTION WITH RELA.
RX   PubMed=15616592; DOI=10.1038/sj.emboj.7600500;
RA   Covic M., Hassa P.O., Saccani S., Buerki C., Meier N.I., Lombardi C.,
RA   Imhof R., Bedford M.T., Natoli G., Hottiger M.O.;
RT   "Arginine methyltransferase CARM1 is a promoter-specific regulator of NF-
RT   kappaB-dependent gene expression.";
RL   EMBO J. 24:85-96(2005).
RN   [20]
RP   TISSUE SPECIFICITY.
RX   PubMed=16508003; DOI=10.1128/mcb.26.6.2273-2285.2006;
RA   Fujiwara T., Mori Y., Chu D.L., Koyama Y., Miyata S., Tanaka H., Yachi K.,
RA   Kubo T., Yoshikawa H., Tohyama M.;
RT   "CARM1 regulates proliferation of PC12 cells by methylating HuD.";
RL   Mol. Cell. Biol. 26:2273-2285(2006).
RN   [21]
RP   FUNCTION, INTERACTION WITH TRIM24, AND IDENTIFICATION IN A COMPLEX WITH
RP   TRIM24 AND NCOA2.
RX   PubMed=16322096; DOI=10.1210/me.2005-0393;
RA   Teyssier C., Ou C.Y., Khetchoumian K., Losson R., Stallcup M.R.;
RT   "Transcriptional intermediary factor 1alpha mediates physical interaction
RT   and functional synergy between the coactivator-associated arginine
RT   methyltransferase 1 and glucocorticoid receptor-interacting protein 1
RT   nuclear receptor coactivators.";
RL   Mol. Endocrinol. 20:1276-1286(2006).
RN   [22]
RP   FUNCTION.
RX   PubMed=17218272; DOI=10.1016/j.molcel.2006.11.019;
RA   Cheng D., Cote J., Shaaban S., Bedford M.T.;
RT   "The arginine methyltransferase CARM1 regulates the coupling of
RT   transcription and mRNA processing.";
RL   Mol. Cell 25:71-83(2007).
RN   [23]
RP   DISRUPTION PHENOTYPE, AND FUNCTION.
RX   PubMed=18188184; DOI=10.1038/sj.embor.7401151;
RA   Yadav N., Cheng D., Richard S., Morel M., Iyer V.R., Aldaz C.M.,
RA   Bedford M.T.;
RT   "CARM1 promotes adipocyte differentiation by coactivating PPARgamma.";
RL   EMBO Rep. 9:193-198(2008).
RN   [24]
RP   FUNCTION, CATALYTIC ACTIVITY, SUBUNIT, INTERACTION WITH EP300 AND NCOA3,
RP   SUBCELLULAR LOCATION, MUTAGENESIS OF TYR-154; SER-217 AND SER-229, AND
RP   PHOSPHORYLATION AT SER-217.
RX   PubMed=19843527; DOI=10.1074/jbc.m109.065524;
RA   Feng Q., He B., Jung S.Y., Song Y., Qin J., Tsai S.Y., Tsai M.J.,
RA   O'Malley B.W.;
RT   "Biochemical control of CARM1 enzymatic activity by phosphorylation.";
RL   J. Biol. Chem. 284:36167-36174(2009).
RN   [25]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Brain, Heart, Spleen, and Testis;
RX   PubMed=21183079; DOI=10.1016/j.cell.2010.12.001;
RA   Huttlin E.L., Jedrychowski M.P., Elias J.E., Goswami T., Rad R.,
RA   Beausoleil S.A., Villen J., Haas W., Sowa M.E., Gygi S.P.;
RT   "A tissue-specific atlas of mouse protein phosphorylation and expression.";
RL   Cell 143:1174-1189(2010).
RN   [26]
RP   FUNCTION, CATALYTIC ACTIVITY, DISRUPTION PHENOTYPE, SUBUNIT, AND
RP   MUTAGENESIS OF ARG-169 AND TYR-173.
RX   PubMed=19897492; DOI=10.1074/jbc.m109.035865;
RA   Kim D., Lee J., Cheng D., Li J., Carter C., Richie E., Bedford M.T.;
RT   "Enzymatic activity is required for the in vivo functions of CARM1.";
RL   J. Biol. Chem. 285:1147-1152(2010).
RN   [27]
RP   METHYLATION AT ARG-551, FUNCTION, CATALYTIC ACTIVITY, MUTAGENESIS OF
RP   ARG-551, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=21138967; DOI=10.1093/nar/gkq1246;
RA   Kuhn P., Chumanov R., Wang Y., Ge Y., Burgess R.R., Xu W.;
RT   "Automethylation of CARM1 allows coupling of transcription and mRNA
RT   splicing.";
RL   Nucleic Acids Res. 39:2717-2726(2011).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 147-490 IN COMPLEX WITH
RP   S-ADENOSYL-L-HOMOCYSTEINE, CATALYTIC ACTIVITY, FUNCTION, INTERACTION WITH
RP   NCOA2/GRIP1, ACTIVITY REGULATION, AND SUBUNIT.
RX   PubMed=17882261; DOI=10.1038/sj.emboj.7601856;
RA   Yue W.W., Hassler M., Roe S.M., Thompson-Vale V., Pearl L.H.;
RT   "Insights into histone code syntax from structural and biochemical studies
RT   of CARM1 methyltransferase.";
RL   EMBO J. 26:4402-4412(2007).
CC   -!- FUNCTION: Methylates (mono- and asymmetric dimethylation) the guanidino
CC       nitrogens of arginyl residues in several proteins involved in DNA
CC       packaging, transcription regulation, pre-mRNA splicing, and mRNA
CC       stability. Recruited to promoters upon gene activation together with
CC       histone acetyltransferases from EP300/P300 and p160 families,
CC       methylates histone H3 at 'Arg-17' (H3R17me), forming mainly asymmetric
CC       dimethylarginine (H3R17me2a), leading to activates transcription via
CC       chromatin remodeling. During nuclear hormone receptor activation and
CC       TCF7L2/TCF4 activation, acts synergically with EP300/P300 and either
CC       one of the p160 histone acetyltransferases NCOA1/SRC1, NCOA2/GRIP1 and
CC       NCOA3/ACTR or CTNNB1/beta-catenin to activate transcription. During
CC       myogenic transcriptional activation, acts together with NCOA3/ACTR as a
CC       coactivator for MEF2C. During monocyte inflammatory stimulation, acts
CC       together with EP300/P300 as a coactivator for NF-kappa-B. Acts as
CC       coactivator for PPARG, promotes adipocyte differentiation and the
CC       accumulation of brown fat tissue. Plays a role in the regulation of
CC       pre-mRNA alternative splicing by methylation of splicing factors. Also
CC       seems to be involved in p53/TP53 transcriptional activation. Methylates
CC       EP300/P300, both at 'Arg-2142', which may loosen its interaction with
CC       NCOA2/GRIP1, and at 'Arg-580' and 'Arg-604' in the KIX domain, which
CC       impairs its interaction with CREB and inhibits CREB-dependent
CC       transcriptional activation. Also methylates arginine residues in RNA-
CC       binding proteins PABPC1, ELAVL1 and ELAV4, which may affect their mRNA-
CC       stabilizing properties and the half-life of their target mRNAs.
CC       {ECO:0000269|PubMed:10381882, ECO:0000269|PubMed:11341840,
CC       ECO:0000269|PubMed:11701890, ECO:0000269|PubMed:11713257,
CC       ECO:0000269|PubMed:11983685, ECO:0000269|PubMed:11997499,
CC       ECO:0000269|PubMed:12756295, ECO:0000269|PubMed:14966289,
CC       ECO:0000269|PubMed:15186775, ECO:0000269|PubMed:15616592,
CC       ECO:0000269|PubMed:16322096, ECO:0000269|PubMed:17218272,
CC       ECO:0000269|PubMed:17882261, ECO:0000269|PubMed:18188184,
CC       ECO:0000269|PubMed:19843527, ECO:0000269|PubMed:19897492,
CC       ECO:0000269|PubMed:21138967}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-arginyl-[protein] + 2 S-adenosyl-L-methionine = 2 H(+) +
CC         N(omega),N(omega)-dimethyl-L-arginyl-[protein] + 2 S-adenosyl-L-
CC         homocysteine; Xref=Rhea:RHEA:48096, Rhea:RHEA-COMP:10532, Rhea:RHEA-
CC         COMP:11991, ChEBI:CHEBI:15378, ChEBI:CHEBI:29965, ChEBI:CHEBI:57856,
CC         ChEBI:CHEBI:59789, ChEBI:CHEBI:61897; EC=2.1.1.319;
CC         Evidence={ECO:0000269|PubMed:11341840, ECO:0000269|PubMed:17882261,
CC         ECO:0000269|PubMed:19843527, ECO:0000269|PubMed:19897492,
CC         ECO:0000269|PubMed:21138967};
CC   -!- ACTIVITY REGULATION: Methylation of H3R17 (H3R17me) by CARM1 is
CC       stimulated by preacetylation of H3 'Lys-18' (H3K18ac) H3 'Lys-23'
CC       (H3K23ac) by EP300 and blocked by citrullination of H3 'Arg-17'
CC       (H3R17ci) by PADI4. {ECO:0000269|PubMed:17882261}.
CC   -!- SUBUNIT: Homodimer. Interacts with NR1H4. Interacts with SNRPC (By
CC       similarity). Interacts with the C-terminus of NCOA2/GRIP1, NCO3/ACTR
CC       and NCOA1/SRC1. Part of a complex consisting of CARM1, EP300/P300 and
CC       NCOA2/GRIP1. Interacts with FLII, TP53, myogenic factor MEF2,
CC       EP300/P300, TRIM24, CREBBP and CTNNB1. Interacts with RELA. Identified
CC       in a complex containing CARM1, TRIM24 and NCOA2/GRIP1. Interacts with
CC       NCOA3/SRC3. {ECO:0000250, ECO:0000269|PubMed:10381882,
CC       ECO:0000269|PubMed:11701890, ECO:0000269|PubMed:11713257,
CC       ECO:0000269|PubMed:11983685, ECO:0000269|PubMed:11997499,
CC       ECO:0000269|PubMed:14966289, ECO:0000269|PubMed:15186775,
CC       ECO:0000269|PubMed:15616592, ECO:0000269|PubMed:16322096,
CC       ECO:0000269|PubMed:17882261, ECO:0000269|PubMed:19843527,
CC       ECO:0000269|PubMed:19897492}.
CC   -!- SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Mainly nuclear during
CC       the G1, S and G2 phases of the cell cycle. Cytoplasmic during mitosis,
CC       after breakup of the nuclear membrane (By similarity). {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9WVG6-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9WVG6-2; Sequence=VSP_012508;
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed. Within the brain, present
CC       in proliferating cells from lateral ventricular zone and dentate gyrus
CC       (at protein level). {ECO:0000269|PubMed:10381882,
CC       ECO:0000269|PubMed:16508003}.
CC   -!- DEVELOPMENTAL STAGE: At 9 dpc, expression is prominent in the neural
CC       tube and somites. {ECO:0000269|PubMed:11713257}.
CC   -!- PTM: Phosphorylation at Ser-217 is strongly increased during mitosis,
CC       and decreases rapidly to a very low, basal level after entry into the
CC       G1 phase of the cell cycle (By similarity). Phosphorylation at Ser-217
CC       interferes with S-adenosyl-L-methionine binding and strongly reduces
CC       methyltransferase activity. Phosphorylation at Ser-217 may promote
CC       cytosolic location. {ECO:0000250, ECO:0000269|PubMed:19843527}.
CC   -!- PTM: Auto-methylated on Arg-551. Methylation enhances transcription
CC       coactivator activity. Methylation is required for its role in the
CC       regulation of pre-mRNA alternative splicing.
CC       {ECO:0000269|PubMed:10381882, ECO:0000269|PubMed:11701890,
CC       ECO:0000269|PubMed:11747826, ECO:0000269|PubMed:11751582,
CC       ECO:0000269|PubMed:11850402, ECO:0000269|PubMed:12237300,
CC       ECO:0000269|PubMed:12498683, ECO:0000269|PubMed:12756295,
CC       ECO:0000269|PubMed:15339660, ECO:0000269|PubMed:15616592,
CC       ECO:0000269|PubMed:21138967}.
CC   -!- DISRUPTION PHENOTYPE: Neonatal lethality. The lungs of neonates do not
CC       inflate and they do not breathe. The same neonate lethality is observed
CC       with mutants that produce CARM1 protein without enzyme activity.
CC       Embryos are distinctly smaller at 18.5 dpc. They show reduced lipid
CC       accumulation in brown adipose tissue and reduced amounts of brown
CC       adipose tissue. Thymocyte differentiation is blocked at an early stage.
CC       Mutants display complete loss of protein methylation of the CARM1
CC       substrates PABPC1 and EP300/P300. {ECO:0000269|PubMed:12756295,
CC       ECO:0000269|PubMed:18188184, ECO:0000269|PubMed:19897492}.
CC   -!- SIMILARITY: Belongs to the class I-like SAM-binding methyltransferase
CC       superfamily. Protein arginine N-methyltransferase family.
CC       {ECO:0000255|PROSITE-ProRule:PRU01015}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF117887; AAD41265.2; -; mRNA.
DR   EMBL; BC003964; AAH03964.1; -; mRNA.
DR   EMBL; BC008263; AAH08263.1; -; mRNA.
DR   EMBL; BC036974; AAH36974.1; -; mRNA.
DR   EMBL; AK158757; BAE34644.1; -; mRNA.
DR   CCDS; CCDS22906.1; -. [Q9WVG6-1]
DR   CCDS; CCDS52736.1; -. [Q9WVG6-2]
DR   RefSeq; NP_067506.2; NM_021531.6. [Q9WVG6-1]
DR   RefSeq; NP_694781.1; NM_153141.1. [Q9WVG6-2]
DR   PDB; 2V74; X-ray; 2.70 A; B/D/F/H=147-490.
DR   PDB; 2V7E; X-ray; 2.70 A; A/B=147-490.
DR   PDB; 5IH3; X-ray; 1.77 A; A/B/C/D=130-487.
DR   PDB; 5IS6; X-ray; 2.01 A; A/B/C/D=130-487.
DR   PDB; 5IS7; X-ray; 2.29 A; A/B/C/D=130-487.
DR   PDB; 5IS8; X-ray; 2.71 A; A/B/C/D=130-507.
DR   PDB; 5IS9; X-ray; 2.40 A; A/B/C/D=130-487.
DR   PDB; 5ISA; X-ray; 2.40 A; A/B/C/D=130-490.
DR   PDB; 5ISB; X-ray; 2.00 A; A/B/C/D=130-487.
DR   PDB; 5ISC; X-ray; 2.60 A; A/B/C/D=130-487.
DR   PDB; 5ISD; X-ray; 2.60 A; A/B/C/D=130-487.
DR   PDB; 5ISE; X-ray; 2.10 A; A/B/C/D=130-487.
DR   PDB; 5ISF; X-ray; 2.22 A; A/B/C/D=130-487.
DR   PDB; 5ISG; X-ray; 2.42 A; A/B/C/D=130-487.
DR   PDB; 5ISH; X-ray; 2.15 A; A/B/C/D=130-487.
DR   PDB; 5ISI; X-ray; 2.74 A; A/B/C/D=130-487.
DR   PDB; 5K8V; X-ray; 2.25 A; A/B/C/D=130-487.
DR   PDB; 5K8W; X-ray; 2.10 A; A/B/C/D=130-487.
DR   PDB; 5K8X; X-ray; 1.99 A; A/B/C/D=130-487.
DR   PDB; 5LGP; X-ray; 2.04 A; A/B/C/D=130-487.
DR   PDB; 5LGQ; X-ray; 2.11 A; A/B/C/D=130-487.
DR   PDB; 5LGR; X-ray; 2.00 A; A/B/C/D=130-487.
DR   PDB; 5LGS; X-ray; 2.10 A; A/B/C/D=130-487.
DR   PDB; 5LKJ; X-ray; 2.60 A; A/B/C/D=130-497.
DR   PDB; 5LV2; X-ray; 2.29 A; A/B/C/D/E/F/G/H=130-487.
DR   PDB; 5LV3; X-ray; 1.80 A; A/B/C/D=130-487.
DR   PDB; 5NTC; X-ray; 2.25 A; A/B/C/D=130-497.
DR   PDB; 5TBH; X-ray; 2.34 A; A/B/C/D=130-487.
DR   PDB; 5TBI; X-ray; 2.29 A; A/B/C/D=130-487.
DR   PDB; 5TBJ; X-ray; 2.32 A; A/B/C/D=130-487.
DR   PDBsum; 2V74; -.
DR   PDBsum; 2V7E; -.
DR   PDBsum; 5IH3; -.
DR   PDBsum; 5IS6; -.
DR   PDBsum; 5IS7; -.
DR   PDBsum; 5IS8; -.
DR   PDBsum; 5IS9; -.
DR   PDBsum; 5ISA; -.
DR   PDBsum; 5ISB; -.
DR   PDBsum; 5ISC; -.
DR   PDBsum; 5ISD; -.
DR   PDBsum; 5ISE; -.
DR   PDBsum; 5ISF; -.
DR   PDBsum; 5ISG; -.
DR   PDBsum; 5ISH; -.
DR   PDBsum; 5ISI; -.
DR   PDBsum; 5K8V; -.
DR   PDBsum; 5K8W; -.
DR   PDBsum; 5K8X; -.
DR   PDBsum; 5LGP; -.
DR   PDBsum; 5LGQ; -.
DR   PDBsum; 5LGR; -.
DR   PDBsum; 5LGS; -.
DR   PDBsum; 5LKJ; -.
DR   PDBsum; 5LV2; -.
DR   PDBsum; 5LV3; -.
DR   PDBsum; 5NTC; -.
DR   PDBsum; 5TBH; -.
DR   PDBsum; 5TBI; -.
DR   PDBsum; 5TBJ; -.
DR   SMR; Q9WVG6; -.
DR   BioGRID; 208501; 24.
DR   DIP; DIP-44593N; -.
DR   IntAct; Q9WVG6; 8.
DR   MINT; Q9WVG6; -.
DR   STRING; 10090.ENSMUSP00000034703; -.
DR   BindingDB; Q9WVG6; -.
DR   ChEMBL; CHEMBL5538; -.
DR   iPTMnet; Q9WVG6; -.
DR   PhosphoSitePlus; Q9WVG6; -.
DR   PaxDb; Q9WVG6; -.
DR   PRIDE; Q9WVG6; -.
DR   ProteomicsDB; 279910; -. [Q9WVG6-1]
DR   ProteomicsDB; 279911; -. [Q9WVG6-2]
DR   Antibodypedia; 25589; 624 antibodies.
DR   Ensembl; ENSMUST00000034703; ENSMUSP00000034703; ENSMUSG00000032185. [Q9WVG6-1]
DR   Ensembl; ENSMUST00000115395; ENSMUSP00000111053; ENSMUSG00000032185. [Q9WVG6-2]
DR   GeneID; 59035; -.
DR   KEGG; mmu:59035; -.
DR   UCSC; uc009olu.2; mouse. [Q9WVG6-1]
DR   UCSC; uc009olw.2; mouse. [Q9WVG6-2]
DR   CTD; 10498; -.
DR   MGI; MGI:1913208; Carm1.
DR   eggNOG; KOG1500; Eukaryota.
DR   GeneTree; ENSGT00940000160377; -.
DR   HOGENOM; CLU_017375_0_1_1; -.
DR   InParanoid; Q9WVG6; -.
DR   OMA; FHILQTG; -.
DR   OrthoDB; 840669at2759; -.
DR   PhylomeDB; Q9WVG6; -.
DR   TreeFam; TF323332; -.
DR   Reactome; R-MMU-3214858; RMTs methylate histone arginines.
DR   Reactome; R-MMU-400206; Regulation of lipid metabolism by PPARalpha.
DR   Reactome; R-MMU-9018519; Estrogen-dependent gene expression.
DR   BioGRID-ORCS; 59035; 10 hits in 55 CRISPR screens.
DR   ChiTaRS; Carm1; mouse.
DR   EvolutionaryTrace; Q9WVG6; -.
DR   PRO; PR:Q9WVG6; -.
DR   Proteomes; UP000000589; Chromosome 9.
DR   RNAct; Q9WVG6; protein.
DR   Bgee; ENSMUSG00000032185; Expressed in internal carotid artery and 324 other tissues.
DR   ExpressionAtlas; Q9WVG6; baseline and differential.
DR   Genevisible; Q9WVG6; MM.
DR   GO; GO:0005737; C:cytoplasm; ISO:MGI.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; ISO:MGI.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0032991; C:protein-containing complex; IDA:MGI.
DR   GO; GO:0090575; C:RNA polymerase II transcription regulator complex; IDA:MGI.
DR   GO; GO:0042054; F:histone methyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0035642; F:histone methyltransferase activity (H3-R17 specific); IDA:UniProtKB.
DR   GO; GO:0008469; F:histone-arginine N-methyltransferase activity; ISO:MGI.
DR   GO; GO:0070577; F:lysine-acetylated histone binding; IDA:UniProtKB.
DR   GO; GO:0030374; F:nuclear receptor coactivator activity; IDA:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:UniProtKB.
DR   GO; GO:0008276; F:protein methyltransferase activity; IDA:MGI.
DR   GO; GO:0016274; F:protein-arginine N-methyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0035242; F:protein-arginine omega-N asymmetric methyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0003713; F:transcription coactivator activity; IDA:UniProtKB.
DR   GO; GO:0000976; F:transcription regulatory region sequence-specific DNA binding; IMP:UniProtKB.
DR   GO; GO:0060350; P:endochondral bone morphogenesis; IMP:MGI.
DR   GO; GO:0034969; P:histone arginine methylation; IDA:UniProtKB.
DR   GO; GO:0034971; P:histone H3-R17 methylation; IDA:UniProtKB.
DR   GO; GO:0034970; P:histone H3-R2 methylation; ISO:MGI.
DR   GO; GO:0016571; P:histone methylation; IDA:MGI.
DR   GO; GO:0030520; P:intracellular estrogen receptor signaling pathway; IGI:MGI.
DR   GO; GO:0030518; P:intracellular steroid hormone receptor signaling pathway; IDA:HGNC-UCL.
DR   GO; GO:2000171; P:negative regulation of dendrite development; ISO:MGI.
DR   GO; GO:0032091; P:negative regulation of protein binding; IDA:MGI.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IMP:MGI.
DR   GO; GO:0045600; P:positive regulation of fat cell differentiation; IMP:UniProtKB.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IMP:MGI.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IGI:MGI.
DR   GO; GO:0071168; P:protein localization to chromatin; IMP:MGI.
DR   GO; GO:0006479; P:protein methylation; IMP:MGI.
DR   GO; GO:0003420; P:regulation of growth plate cartilage chondrocyte proliferation; IMP:MGI.
DR   GO; GO:0033146; P:regulation of intracellular estrogen receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:1902415; P:regulation of mRNA binding; ISO:MGI.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IDA:MGI.
DR   GO; GO:0051591; P:response to cAMP; ISO:MGI.
DR   Gene3D; 2.30.29.30; -; 1.
DR   InterPro; IPR025799; Arg_MeTrfase.
DR   InterPro; IPR020989; Histone-Arg_MeTrfase_N.
DR   InterPro; IPR011993; PH-like_dom_sf.
DR   InterPro; IPR029063; SAM-dependent_MTases.
DR   Pfam; PF11531; CARM1; 1.
DR   SUPFAM; SSF53335; SSF53335; 1.
DR   PROSITE; PS51678; SAM_MT_PRMT; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Chromatin regulator; Cytoplasm;
KW   Methylation; Methyltransferase; Nucleus; Phosphoprotein;
KW   Reference proteome; S-adenosyl-L-methionine; Transcription;
KW   Transcription regulation; Transferase.
FT   CHAIN           1..608
FT                   /note="Histone-arginine methyltransferase CARM1"
FT                   /id="PRO_0000212339"
FT   DOMAIN          147..454
FT                   /note="SAM-dependent MTase PRMT-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01015"
FT   REGION          500..608
FT                   /note="Transactivation domain"
FT   BINDING         160
FT                   /note="S-adenosyl-L-methionine"
FT   BINDING         169
FT                   /note="S-adenosyl-L-methionine"
FT   BINDING         193
FT                   /note="S-adenosyl-L-methionine; via carbonyl oxygen"
FT   BINDING         215
FT                   /note="S-adenosyl-L-methionine"
FT   BINDING         244
FT                   /note="S-adenosyl-L-methionine"
FT   BINDING         272
FT                   /note="S-adenosyl-L-methionine"
FT   MOD_RES         217
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:19843527"
FT   MOD_RES         551
FT                   /note="Dimethylated arginine"
FT                   /evidence="ECO:0000269|PubMed:21138967"
FT   VAR_SEQ         540..562
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_012508"
FT   MUTAGEN         154
FT                   /note="Y->A,F,R: Loss of S-adenosyl-L-methionine binding.
FT                   Loss of protein methyltransferase activity."
FT                   /evidence="ECO:0000269|PubMed:19843527"
FT   MUTAGEN         169
FT                   /note="R->A: Loss of protein methyltransferase activity."
FT                   /evidence="ECO:0000269|PubMed:19897492"
FT   MUTAGEN         173
FT                   /note="Y->A: Reduces protein methyltransferase activity."
FT                   /evidence="ECO:0000269|PubMed:19897492"
FT   MUTAGEN         189..191
FT                   /note="VLD->AAA: Abolishes histone methyltransferase
FT                   activity and coactivator activity."
FT                   /evidence="ECO:0000269|PubMed:10381882,
FT                   ECO:0000269|PubMed:11701890"
FT   MUTAGEN         217
FT                   /note="S->A: Loss of S-adenosyl-L-methionine binding. Loss
FT                   of protein methyltransferase activity. Localized in the
FT                   nucleus."
FT                   /evidence="ECO:0000269|PubMed:19843527"
FT   MUTAGEN         217
FT                   /note="S->C,T: Loss of S-adenosyl-L-methionine binding.
FT                   Loss of protein methyltransferase activity."
FT                   /evidence="ECO:0000269|PubMed:19843527"
FT   MUTAGEN         217
FT                   /note="S->E: Loss of S-adenosyl-L-methionine binding. Loss
FT                   of protein methyltransferase activity. Localized in the
FT                   cytosol."
FT                   /evidence="ECO:0000269|PubMed:19843527"
FT   MUTAGEN         229
FT                   /note="S->E: Abolishes dimerization."
FT                   /evidence="ECO:0000269|PubMed:19843527"
FT   MUTAGEN         267
FT                   /note="E->Q: Abolishes histone methyltransferase activity
FT                   and reduces coactivator activity."
FT                   /evidence="ECO:0000269|PubMed:11983685,
FT                   ECO:0000269|PubMed:11997499"
FT   MUTAGEN         551
FT                   /note="R->K: Abolishes dimethylation. Impairs transcription
FT                   coactivator activity and regulation of alternative
FT                   splicing. No effect on methyltransferase activity."
FT                   /evidence="ECO:0000269|PubMed:21138967"
FT   CONFLICT        400
FT                   /note="I -> L (in Ref. 3; BAE34644)"
FT                   /evidence="ECO:0000305"
FT   HELIX           137..141
FT                   /evidence="ECO:0007744|PDB:5IH3"
FT   HELIX           144..154
FT                   /evidence="ECO:0007744|PDB:5IH3"
FT   HELIX           157..164
FT                   /evidence="ECO:0007744|PDB:5IH3"
FT   HELIX           167..179
FT                   /evidence="ECO:0007744|PDB:5IH3"
FT   HELIX           181..183
FT                   /evidence="ECO:0007744|PDB:5IH3"
FT   TURN            184..186
FT                   /evidence="ECO:0007744|PDB:5IH3"
FT   STRAND          188..193
FT                   /evidence="ECO:0007744|PDB:5IH3"
FT   TURN            195..197
FT                   /evidence="ECO:0007744|PDB:5K8V"
FT   HELIX           198..205
FT                   /evidence="ECO:0007744|PDB:5IH3"
FT   STRAND          209..215
FT                   /evidence="ECO:0007744|PDB:5IH3"
FT   HELIX           219..229
FT                   /evidence="ECO:0007744|PDB:5IH3"
FT   TURN            233..235
FT                   /evidence="ECO:0007744|PDB:5IH3"
FT   STRAND          236..241
FT                   /evidence="ECO:0007744|PDB:5IH3"
FT   TURN            243..245
FT                   /evidence="ECO:0007744|PDB:5IH3"
FT   STRAND          252..257
FT                   /evidence="ECO:0007744|PDB:5IH3"
FT   TURN            265..267
FT                   /evidence="ECO:0007744|PDB:5IH3"
FT   HELIX           269..275
FT                   /evidence="ECO:0007744|PDB:5IH3"
FT   HELIX           276..279
FT                   /evidence="ECO:0007744|PDB:5IH3"
FT   STRAND          280..288
FT                   /evidence="ECO:0007744|PDB:5IH3"
FT   STRAND          290..298
FT                   /evidence="ECO:0007744|PDB:5IH3"
FT   HELIX           301..311
FT                   /evidence="ECO:0007744|PDB:5IH3"
FT   HELIX           312..314
FT                   /evidence="ECO:0007744|PDB:5IH3"
FT   STRAND          319..321
FT                   /evidence="ECO:0007744|PDB:2V74"
FT   HELIX           325..327
FT                   /evidence="ECO:0007744|PDB:5IH3"
FT   HELIX           328..336
FT                   /evidence="ECO:0007744|PDB:5IH3"
FT   STRAND          340..342
FT                   /evidence="ECO:0007744|PDB:5IH3"
FT   HELIX           346..348
FT                   /evidence="ECO:0007744|PDB:5IH3"
FT   STRAND          354..359
FT                   /evidence="ECO:0007744|PDB:5IH3"
FT   TURN            360..362
FT                   /evidence="ECO:0007744|PDB:5IH3"
FT   HELIX           365..368
FT                   /evidence="ECO:0007744|PDB:5IH3"
FT   STRAND          369..378
FT                   /evidence="ECO:0007744|PDB:5IH3"
FT   STRAND          383..397
FT                   /evidence="ECO:0007744|PDB:5IH3"
FT   STRAND          402..406
FT                   /evidence="ECO:0007744|PDB:5IH3"
FT   STRAND          418..429
FT                   /evidence="ECO:0007744|PDB:5IH3"
FT   STRAND          434..444
FT                   /evidence="ECO:0007744|PDB:5IH3"
FT   TURN            445..447
FT                   /evidence="ECO:0007744|PDB:5IH3"
FT   STRAND          448..457
FT                   /evidence="ECO:0007744|PDB:5IH3"
FT   TURN            458..460
FT                   /evidence="ECO:0007744|PDB:5IH3"
FT   STRAND          463..469
FT                   /evidence="ECO:0007744|PDB:5IH3"
FT   TURN            494..496
FT                   /evidence="ECO:0007744|PDB:5IS8"
SQ   SEQUENCE   608 AA;  65854 MW;  C621F2AA9FBA2DA3 CRC64;
     MAAAAATAVG PGAGSAGVAG PGGAGPCATV SVFPGARLLT IGDANGEIQR HAEQQALRLE
     VRAGPDAAGI ALYSHEDVCV FKCSVSRETE CSRVGRQSFI ITLGCNSVLI QFATPHDFCS
     FYNILKTCRG HTLERSVFSE RTEESSAVQY FQFYGYLSQQ QNMMQDYVRT GTYQRAILQN
     HTDFKDKIVL DVGCGSGILS FFAAQAGARK IYAVEASTMA QHAEVLVKSN NLTDRIVVIP
     GKVEEVSLPE QVDIIISEPM GYMLFNERML ESYLHAKKYL KPSGNMFPTI GDVHLAPFTD
     EQLYMEQFTK ANFWYQPSFH GVDLSALRGA AVDEYFRQPV VDTFDIRILM AKSVKYTVNF
     LEAKEGDLHR IEIPFKFHML HSGLVHGLAF WFDVAFIGSI MTVWLSTAPT EPLTHWYQVR
     CLFQSPLFAK AGDTLSGTCL LIANKRQSYD ISIVAQVDQT GSKSSNLLDL KNPFFRYTGT
     TPSPPPGSHY TSPSENMWNT GSTYNLSSGV AVAGMPTAYD LSSVIAGGSS VGHNNLIPLA
     NTGIVNHTHS RMGSIMSTGI VQGSSGAQGG GGSSSAHYAV NNQFTMGGPA ISMASPMSIP
     TNTMHYGS
//
